Today: 7 February 2026
Subscribe
Browse Category

NYSE:NVS News 16 September 2025 - 31 January 2026

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

New York, Jan 12, 2026, 07:52 EST — Premarket Tempus AI shares climbed roughly 12%, reaching $74.34 in Monday’s premarket session. (Investing.com) The bid emerged amid a volatile morning for growth stocks, with Nasdaq 100 futures slipping close to 1% as investors digested fresh doubts over the Federal Reserve’s independence and prepared for earnings season to begin. (Reuters) Tempus projected full-year 2025 revenue around $1.27 billion in an SEC filing, marking an 83% jump from the previous year. That includes roughly 30% organic growth without Ambry. Diagnostics revenue hit about $955 million, soaring 111%, while data and applications brought in
12 January 2026
······
Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

New York, Jan 12, 2026, 05:29 EST — Premarket Tempus AI, Inc. shares were up about 11% in premarket trading on Monday after the company flagged strong preliminary 2025 results and reported record contract value with drugmakers. Tempus AI traded at $73.66 in premarket action, after ending Friday at $66.27. (google.com) The update lands as investors head into the annual J.P. Morgan Healthcare Conference week, when companies often try to reset expectations and pitch their 2026 story. Tempus has been a high-beta name in that mix, moving sharply on growth signals. For Tempus, the market focus has narrowed to two
12 January 2026
·······
Novartis stock on watch as Florida radioligand plant plan tees up JPM conference week

Novartis stock on watch as Florida radioligand plant plan tees up JPM conference week

New York, January 11, 2026, 14:15 EST — Market closed. Novartis AG’s U.S.-listed shares (NVS) closed Friday mostly flat. Still, the stock starts the new week with a notable development: the company announced a new U.S. manufacturing facility for its radioligand cancer therapies. (Novartis) The timing matters because radioligand therapy demands tight logistics — every dose is tailored to a single patient, and the clock is ticking the moment it’s prepared. More capacity and smarter location choices mean fewer missed or delayed treatments. Novartis has been pushing that point hard, and investors are taking note. (Novartis) The timing coincides with
11 January 2026
··
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered around Dec. 19–21, 2025. From the White House’s sweeping “most-favored-nation” (MFN) push on U.S. drug prices to BioMarin’s largest-ever acquisition and fresh FDA approvals, the setup into year-end has become more headline-sensitive than the calendar would suggest. Here’s what investors and traders should be watching in pharma stocks in the week ahead. Christmas week trading: shorter sessions, fewer buyers, faster
21 December 2025
·········
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

As of December 20, 2025, healthcare stocks are heading into year-end with a rare mix of policy clarity and policy risk—often at the same time. In the past 48 hours, the sector has been hit by major U.S. drug-pricing announcements, renewed focus on insurance premiums, and a fresh run of deal and IPO headlines that are reshaping investor expectations for 2026. Reuters+3Reuters+3Reuters+3 Below is a comprehensive roundup of the most market-moving healthcare news, plus the latest forecasts and sector analysis shaping how investors are positioning across pharma, biotech, managed care, medtech, and healthcare services into 2026. 1) Drug pricing is
20 December 2025
········
Salesforce (CRM) Stock After Hours Today (Dec. 17, 2025): Qualified Acquisition, Novartis Agentforce Deal, Analyst Forecasts, and What to Watch Before the Market Opens

Salesforce (CRM) Stock After Hours Today (Dec. 17, 2025): Qualified Acquisition, Novartis Agentforce Deal, Analyst Forecasts, and What to Watch Before the Market Opens

Salesforce, Inc. (NYSE: CRM) ended Wednesday, December 17, 2025, on a relative high in a tough tape—then edged lower in after-hours trading as investors processed late-day headlines and looked ahead to a potentially market-moving inflation print Thursday morning. Salesforce stock price after the bell: where CRM stands tonight In regular NYSE trading, Salesforce closed at $258.14, up about 1.27% on the day. In after-hours trading, the stock slipped to roughly $257.50 (down ~0.25%) as of around 6:15 p.m. ET. MarketScreener Wednesday’s session showed a wide—but controlled—trading range for CRM: $256.37 (low) to $261.97 (high), with the stock opening near $256.33.
18 December 2025
··
RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Stock Performance & Recent Trends Prior to the buyout news, RNA stock had been on a steady uptrend in 2025. The share price more than doubled from the low-$20s a year ago to the high-$40s this month ts2.tech. In the past three months alone, RNA jumped ~40%, fueled by upbeat clinical updates and M&A speculation ts2.tech. The stock hit a 52-week peak of $56 in early October ts2.tech after its lead DMD therapy showed strong results and secured FDA Breakthrough designation. Shares pulled back slightly to around $49 by late October, but remained up 100%+ year-over-year ts2.tech. A major catalyst
27 October 2025
·····
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Richmond’s New Pharma Giant: Overview of Lilly’s $5B Factory Eli Lilly’s forthcoming Richmond-area factory is set to be one of the largest and most advanced pharmaceutical manufacturing sites in the world. At a cost of $5 billion, Lilly will construct a high-tech production campus in Goochland County’s West Creek Business Park, a site that had been prepped for a previous project and now deemed “the perfect spot” for fast construction Washingtonpost. The facility’s core mission: make more of the critical drug ingredients that Lilly usually sources overseas, right here on U.S. soil Washingtonpost Washingtonpost. Scale and Scope: The plant will
16 September 2025
·······

Stock Market Today

Lucid stock jumps 14% as Dow tops 50,000 — what LCID investors watch next week

Lucid stock jumps 14% as Dow tops 50,000 — what LCID investors watch next week

7 February 2026
Lucid Group shares jumped 14% to $10.86 at Friday’s close, recovering from an 8% drop the previous day. The move followed a broad Wall Street rally that lifted high-volatility stocks. Lucid reported fourth-quarter deliveries of 5,345 vehicles and full-year deliveries of 15,841. Investors await Lucid’s Feb. 24 results for updates on cash and demand.
Go toTop